Cytokinetics CYTK Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $105.82M+451% | $88.04M+377% | $87.21M+2,609% | $85.74M+2,636% | $19.22M+412% | ||
| $411.71M+15.6% | $414.45M+22.1% | $403.68M+22.0% | $389.06M+18.4% | $356.1M+7.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | $284.27M+32.0% | $254.89M+29.3% | $242.08M+34.1% | $227.18M+34.1% | ||
| $11.2M+17.9% | $10.13M+6.2% | $9.65M-28.5% | $9.38M-27.4% | $9.5M-23.2% | ||
| $746.06M+27.6% | $700.3M+26.2% | $660.14M+25.1% | $632.72M+24.3% | $584.86M+16.6% | ||
| $746.06M+27.6% | $700.3M+26.2% | $660.14M+25.1% | $632.72M+24.3% | $584.86M+16.6% | ||
| -$640.25M-13.2% | -$612.26M-14.2% | -$572.93M-9.2% | -$546.98M-8.1% | -$565.64M-13.6% | ||
| -605.1%+2,338pp | -695.4%+2,207pp | -656.9%+15,641pp | -638%+15,510pp | -2,943.3%+10,329pp | ||
| $51.23M+29.8% | $45.58M+20.9% | $40.24M+12.0% | $37.82M+10.8% | $39.47M+38.7% | ||
| $45.74M-20.2% | $48.42M-6.0% | $51.96M+17.8% | $58.77M+73.4% | $57.32M+96.9% | ||
| -$829.61M-34.8% | -$784.96M-33.2% | -$751.94M-30.5% | -$606.31M-11.2% | -$615.26M-16.0% | ||
| -784%+2,417pp | -891.6%+2,300pp | -862.2%+17,044pp | -707.2%+16,692pp | -3,201.5%+10,940pp | ||
| -$6.84-29.3% | -$6.53-24.1% | -$6.29-16.9% | -$5.10+5.0% | -$5.29+2.0% | ||
| -$6.84-29.3% | -$6.53-24.1% | -$6.29-16.9% | -$5.10+5.0% | -$5.29+2.0% | ||
| 482.8M+5.6% | 478M+8.4% | 469.9M+10.5% | 467.6M+15.8% | 457.4M+17.2% | ||
| 482.8M+5.6% | 478M+8.4% | 469.9M+10.5% | 467.6M+15.8% | 457.4M+17.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$832.77M-35.8% | -$786.72M-34.0% | -$757.3M-32.8% | -$605.45M-11.1% | -$613.18M-15.8% | ||
| $6.1M+578% | $4.2M+223% | $4.5M+4,400% | $4.5M+850% | $900K— | ||
| —— | —— | —— | —— | —— | ||
| $4.82M+309% | $1.11M-92.8% | $1.56M— | $8.41M— | $1.18M— | ||
| $41.76M+674% | $33.6M+137% | $17.31M-52.2% | $15.21M-56.4% | $5.39M-72.0% | ||
| $500K+113% | $2.93M+20.3% | $7.18M+149% | $8.98M+186% | -$3.82M-212% | ||
| —— | —— | -$18.1M-20.7% | -$30.5M-15,350% | -$15.7M— | ||
| $527.47M-36.6% | $524.46M-43.6% | $416.14M-62.1% | $89.1M-92.2% | $831.57M+150% | ||
| -$523.85M-31.6% | -$510.01M-28.8% | -$432.93M-7.1% | -$426.92M-7.0% | -$398M+5.6% | ||
| $63.03M+19.7% | $58.29M+19.4% | $55.88M+24.0% | $54.29M+40.8% | $52.67M+58.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$801K-678% | -$952K-4,239% | -$84K-1,300% | ||
| $1.01B-22.8% | $1.06B-17.8% | $838.65M-40.0% | $717.6M-44.9% | $1.31B+90.4% | ||
| $25.07M+162% | $24.81M+535% | $20.45M+659% | $11.8M+433% | $9.57M+844% | ||
| $105.82M+451% | $88.04M+377% | $87.21M+2,609% | $85.74M+2,636% | $19.22M+412% | ||
| $119.13M+19.4% | $112.29M+14.8% | $108.03M+18.6% | $102.69M+21.6% | $99.78M+27.1% | ||
| -$640.25M-13.2% | -$612.26M-14.2% | -$572.93M-9.2% | -$546.98M-8.1% | -$565.64M-13.6% | ||
| -$629.04M-13.1% | -$602.13M-14.3% | -$563.29M-10.2% | -$537.6M-9.0% | -$556.14M-14.5% | ||
| -$629.04M-13.1% | -$602.13M-14.3% | -$563.29M-10.2% | -$537.6M-9.0% | -$556.14M-14.5% | ||
| -594.5%+2,299pp | -683.9%+2,167pp | -645.9%+15,233pp | -627%+15,109pp | -2,893.9%+10,048pp | ||
| -$640.25M-13.2% | -$612.26M-14.2% | -$572.93M-9.2% | -$546.98M-8.1% | -$565.64M-13.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cytokinetics's revenue?
- Cytokinetics (CYTK) generated $105.8M in revenue over the trailing twelve months, up 450.6% year over year.
- Is Cytokinetics profitable?
- Cytokinetics is not currently profitable: it reported a net loss of $829.6M over the trailing twelve months, a -784.0% net margin.
- What is Cytokinetics's earnings per share?
- Cytokinetics's diluted EPS over the trailing twelve months is $-6.84.
- Where does Cytokinetics's income statement data come from?
- Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
